According to Patently-O, the Federal Circuit has denied en banc review in Teva v. Lilly. Judge Dyk filed a dissent from that denial, arguing the full court should have taken up the case. The denial means the earlier panel ruling stands.
The dispute centers on method claims tied to an antibody genus. Patently-O reports that the decision leaves those claims intact after the Supreme Court's Amgen ruling. Judge Dyk's dissent signals continued disagreement over how broadly such method claims may be construed.
Because this is a single source, there are no differing accounts to compare. The report frames the denial as a notable development in the ongoing debate over method versus molecule patent claims.